Announced
Completed
Financials
Sources
Tags
Germany
Friendly
Pharmaceuticals
Acquisition
Majority
drug manufacture
Private
Domestic
Completed
Single Bidder
Synopsis
WuXi Biologics, a global open-access biologics technology platform, completed the acquisition of a Wuppertal facility from Bayer, a global enterprise with core competencies in the Life Science fields of health care and agriculture, for £101m. “This also marks an additional contribution by Bayer in the fight against the pandemic,” Timo Flessner, Bayer Site Manager.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.